SURMONTIL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Surmontil, and what generic alternatives are available?
Surmontil is a drug marketed by Odyssey Pharms and is included in one NDA.
The generic ingredient in SURMONTIL is trimipramine maleate. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the trimipramine maleate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Surmontil
A generic version of SURMONTIL was approved as trimipramine maleate by ELITE LABS INC on August 2nd, 2006.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SURMONTIL?
- What are the global sales for SURMONTIL?
- What is Average Wholesale Price for SURMONTIL?
Summary for SURMONTIL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 48 |
| Patent Applications: | 4,254 |
| Drug Prices: | Drug price information for SURMONTIL |
| DailyMed Link: | SURMONTIL at DailyMed |
US Patents and Regulatory Information for SURMONTIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Odyssey Pharms | SURMONTIL | trimipramine maleate | CAPSULE;ORAL | 016792-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Odyssey Pharms | SURMONTIL | trimipramine maleate | CAPSULE;ORAL | 016792-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Odyssey Pharms | SURMONTIL | trimipramine maleate | CAPSULE;ORAL | 016792-003 | Sep 15, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
